logo
How CDC cuts affect women with chronic diseases like sickle cell

How CDC cuts affect women with chronic diseases like sickle cell

Yahoo11-06-2025
WESTLAND, Mich. — For D'Asia Jackson, every day is a guessing game over whether excruciating pain will upend her life.
The 28-year-old medical assistant was born with sickle cell disease, an inherited condition that causes red blood cells to be shaped like a crescent moon. The anomaly can cause blood clots, organ damage and excruciating pain, which can worsen during the menstrual cycle.
'Pain-wise, I always describe it as like being hit by a Mack truck,' Jackson said. 'When I know my period is coming, I know pain is probably right behind it.'
Over the last 10 years, Jackson has worked with her doctors to try a variety of contraception options to get her symptoms under control, from the Depo-Provera shot, a hormone injection given every three months, to an IUD to different forms of birth control pills.
According to Jackson, none of them helped. Some made her periods even worse.
'I might have a good four or five good days of not bleeding in a month,' she said. 'Over the years, it's like the period actually started getting heavier, and that's when it started affecting my sickle cell.'
At times, she's ended up in the hospital needing iron infusions due to loss of blood. Doctors don't know how to manage her symptoms. Sickle cell has no cure and treatment options are variable.
'The lack of education on sickle cell is very frustrating,' she said. 'I go into hospital stays having to educate doctors and nurses.'
Now, women like Jackson are worried that lack of knowledge, particularly about how contraception affects their conditions, could get worse.
In April, a small team that compiled information into what some consider the country's 'contraception bible,' a set of guidelines used by physicians to assess which types of birth control are safe for their patients, was fired from the Centers for Disease Control and Prevention as part of mass layoffs from the agency. The eight-person team was responsible for evaluating research and recommending birth control methods for patients with various conditions, from sickle cell disease, kidney disease and lupus to those at risk for HIV.
The guidelines, called the U.S. Medical Eligibility Criteria for Contraceptive Use, provided the latest research for doctors, including an app that recommended which contraceptive methods were safe.
The app has been downloaded more than 440,000 times, according to the CDC.
Now, the work of that team has been halted as part of the reduction of the Women's Health and Fertility Branch of the Division of Reproductive Health.
'These are the only federal guidelines that focus on the safety of contraception for women with certain medical conditions,' said Lee Warner, the former chief of the Women's Health and Fertility Branch. 'This work exists nowhere else, and these individuals specialize in this area. Without their presence, the work stops.'
Warner retired from the agency in April just after learning his team was being eliminated.
'While most women are able to use most methods, we looked at 60 conditions and over 1,800 evidence-based recommendations across an array of contraceptive methods,' he said. 'For some women, it is very dangerous for them to become pregnant at a certain point. So having contraception available to them that they can choose can help protect them.'
At least 90% of people in the United States with sickle cell disease are Black. The maternal mortality rate for Black sickle cell patients has been found to be 26 times higher than for non-Black people.
'The CDC's decision to cut the team responsible for contraceptive guidelines is especially troubling for the sickle cell community, where pregnancy can carry severe health risks,' said Teonna Woolford, who founded the nonprofit Sickle Cell Reproductive Health Education Directive to advocate for patients and expand knowledge about the often-misunderstood disease. 'Eliminating this resource will disproportionately impact a community already facing significant barriers to care, further deepening health disparities.'
In response to a request for comment, an official for the Department of Health and Human Services did not explain why the team was cut.
In May, Health Secretary Robert F. Kennedy Jr. defended the cuts in a hearing before the Senate Health, Education, Labor and Pensions Committee.
'Right now we have 42 divisions that do maternal health,' Kennedy testified. 'They're not cuts. They're consolidations. It's ridiculous to have 42 divisions that are all supposed to be doing the same thing.'
Warner disagreed with Kennedy's testimony.
'Especially with this branch,' he said, 'the expertise is not redundant of that elsewhere in the federal government.'
'Once this expertise is gone, it is permanently gone from the agency. It is going to be very hard to resume and re-create,' he said.
'The HHS restructuring consolidates maternal and child health programs into the new Administration for a Healthy America (AHA) to improve efficiency and better address public health needs,' an HHS official said in a statement to NBC News. 'The reorganization aims to streamline operations, maximize resources, and support key priorities like maternal mental health and data collection. We remain committed to improving health outcomes for American families.'
Representatives for HHS did not specify if work on the contraception guidelines would continue. The Trump administration did not respond to questions about why the team was cut or if its work would continue.
The CDC's most recent update to the contraception guidelines was published in August.
The updates included new recommendations for people with sickle cell disease, finding that combined hormonal contraception presents an 'unacceptable health risk' due to patients' risk of life-threatening blood clots. In previous versions of the guidelines, the CDC found the advantages of combined hormonal birth control, which contains estrogen and progestin, outweighed potential risks such as blood clots or stroke. The newest guidelines also increased the risk category for the Depo-Provera shot, while ranking methods like progestin-only pills and IUDs as generally safe.
Jackson was unaware of the updated guidance until her interview with NBC News.
She said she is using an IUD as well as combined hormonal contraception in the form of a pill to try to manage her bleeding.
'I didn't know that,' she said. 'I kind of just hope that my doctor knows a lot and kind of just steers me in the right direction.'
Warner said the CDC team should be publicizing the updated guidance now to make physicians aware of the changes and adjust how they treat patients.
'We actually planned to do a road show of the guidelines in the late fall and throughout the spring in which we would disseminate the guidelines and go speak to provider groups,' he said. 'It's not happening.'
The severe pain associated with her periods has driven Jackson to seek a hysterectomy for relief.
'I have been asking for a hysterectomy for years. I've seen five different OBs, and no one will do it,' she said.
While the current guidelines are still accessible, the August update could be the last, leaving Jackson with little hope that she'll find a method of birth control that works for her.
'I am terrified of how health care is going to go with all of these cuts being made,' she said.
This article was originally published on NBCNews.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)

Yahoo

time14 hours ago

  • Yahoo

Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved Yeztugo® (lenacapavir), Gilead Sciences, Inc. (NASDAQ:GILD)'s injectable HIV-1 capsid inhibitor, as pre-exposure prophylaxis (PrEP) in order to reduce the risk of sexually acquired HIV in adults and adolescents weighing a minimum of 35 kg. The company's Chief Executive added that this medicine is required to be given twice a year, and it has demonstrated strong outcomes in clinical studies, meaning it can transform HIV prevention. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. The approval of Gilead Sciences, Inc. (NASDAQ:GILD)'s New Drug Applications (NDAs) for Yeztugo was supported by data from Phase 3 PURPOSE 1 and PURPOSE 2 trials conducted by the company. In the US, Gilead Sciences, Inc. (NASDAQ:GILD) continues to work closely with insurers, healthcare systems, and other payers, targeting to ensure broad insurance coverage for Yeztugo. Furthermore, for eligible commercially insured individuals with commercial insurance, the company's Advancing Access® Co-Pay Savings Program is expected to reduce out-of-pocket costs to as low as zero dollars. Notably, HIV product sales saw an increase of 6% to $4.6 billion in Q1 2025 as compared to the same period in 2024. This was mainly driven by increased average realized price and demand. Impax Asset Management, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Gilead Sciences, Inc. (NASDAQ:GILD) (Health Care) the company is owned due to its role in solving evolving heath care challenges through the development of new medical treatments for conditions as chronic diseases are on the rise. The company also has one of the highest systematic ESG scores in the portfolio. Gilead reported better-than-expected quarterly results, largely driven by strong revenue from its HIV franchise. The company also provided an optimistic earnings guidance for the next fiscal year, helping provide defensiveness amid a flurry of volatility.' While we acknowledge the potential of GILD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GILD and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

Map Shows States Closing Beaches Over Fecal Bacteria on 4th of July
Map Shows States Closing Beaches Over Fecal Bacteria on 4th of July

Newsweek

time15 hours ago

  • Newsweek

Map Shows States Closing Beaches Over Fecal Bacteria on 4th of July

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Beaches in at least seven states have been closed or issued health advisories due to elevated bacteria levels ahead of the Independence Day holiday weekend. States impacted by the warnings include California, New York, Massachusetts, Washington, Illinois, Michigan, and New Hampshire, according to notices from local health authorities. Why It Matters The Centers for Disease Control and Prevention (CDC) warns that swallowing water contaminated with bacteria can make you ill, including causing gastrointestinal illnesses such as diarrhea. It can also cause infections if you enter the water with an open wound or cut, especially from a piercing or surgery. According to a recent poll by YouGov, 14 percent of Americans plan to celebrate the 4th of July weekend by going to a beach or park. What To Know As of Thursday, beach area warnings were in place for eight locations in Los Angeles County, California, including: Ramirez Creek at Paradise Cove The Bel Air Bay Club at Will Rogers State Beach Mothers Beach in Marina Del Rey Castlerock Storm Drain at Topanga County Beach Santa Monica Pier in Santa Monica Inner Cabrillo Beach in San Pedro Avalon Beach at Catalina Island, 50 feet west of the pier Avalon Beach at Catalina Island, east of the Casino Arch (Steps Beach) The Los Angeles County Department of Public Health said in a statement: "These warnings have been issued due to bacterial levels exceeding health standards when last tested." Visitors were cautioned to avoid swimming, surfing, and playing in the water. File image. A dead fish lies in algae-filled water in Lake Erie in Ohio in 2017. File image. A dead fish lies in algae-filled water in Lake Erie in Ohio in 2017. Andy Morrison/The Blade/AP In New York, at least four beaches were closed to swimming across Nassau and Suffolk counties, including Biltmore Beach, Broadway Beach, Crescent Beach, and Ronkonkoma beach. In Massachusetts, more than a dozen beach closures were in effect due to "bacterial exceedance," according to the Massachusetts Department of Public Health. In Washington's King County, visitors at Houghton, Meydenbauer Bay, and Pritchard Island beaches were advised to stay out of the water due to high bacteria levels. At least eight advisories were issued in Illinois in recent weeks, NBC News reported. High bacteria levels also prompted closures at three Michigan beaches at Camp Ohiyesa, Eagle Lake Road, and Orchard Lake Country Club. Meanwhile in New Hampshire, fecal bacteria advisories were issued on Tuesday for Sandbornton Town Beach and FB Argue Recreation Area Beach. While the above locations were closed due to bacterial contamination, not all specified they were caused by fecal bacteria. What People Are Saying The Environmental Protection Agency says on its website: "Swimming, diving, or wading in water contaminated with fecal bacteria can result in gastrointestinal illness (such as diarrhea or vomiting), respiratory illness, and other health problems. "Skin, ear, eye, sinus, and wound infections can also be caused by contact with contaminated water." What Happens Next Regional health authorities provide regular updates regarding water quality at local beaches.

Theratechnologies shares surge 25% amid $254m Future Pak takeover
Theratechnologies shares surge 25% amid $254m Future Pak takeover

Yahoo

timea day ago

  • Yahoo

Theratechnologies shares surge 25% amid $254m Future Pak takeover

Contract manufacturer Future Pak will acquire Theratechnologies in a $254m deal, bringing an end to a drawn-out sale process of the Canadian HIV-specialist biopharma. Via its affiliate CB Biotechnology, US-headquartered Future Pak will purchase shares in Theratechnologies for $3.01 each plus a contingent value right (CVR) of $1.19 on the achievement of future milestones. Shares in Theratechnologies increased 25% at market open following the takeover announcement. The drugmaker has a market cap of $144.6m. The transaction, which will bring the currently Nasdaq-listed Theratechnologies back under private ownership, means Future Pak is paying a cash premium of 126% on the last closing share price for the biopharma. Theratechnologies has two products in the HIV arena that are approved by the US Food and Drug Administration (FDA), namely Egrifta (tesamorelin F8) and Trogarzo (ibalizumab-uiyk). Egrifta is approved to reduce excess visceral abdominal fat in adults with HIV and lipodystrophy while Trogarzo is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistance. Egrifta WR took over from Egrifta SV in March 2025, offering a more convenient formulation. Expected to close in Q4, the deal will close a sale process that has fluctuated over the past year. Future Pak's first attempt to acquire Theratechnologies was rebuffed in August 2024, with the biopharma deeming the $100m offer too low. Future Pak returned to the deal table in January 2025. Theratechnologies had already entered an exclusivity agreement with another potential acquirer, meaning Future Pak was once again turned away. Theratechnologies eventually opened the sale process to other parties, opening the door for a potential deal with the contract manufacturer. In April 2025, Future Pak tabled a $255 offer, which has now been accepted by the drugmaker. Theratechnologies reported 2024 revenue of $85.9m, a 5% increase from the $81.8m accumulated in 2023. Whilst the company reported a positive EBITDA for the year, it struggled with supply for Egrifta WR due to an issue with a contract manufacturer. Still, sales of the drug grew 12%, unlike Trogarzo, which dropped 8% due to 'competitive pressures' in the multidrug-resistant segment of the HIV market. 'This transaction is the result of a thorough and deliberate sale process aimed at maximising value for our shareholders,' stated Frank Holler, Theratechnologies' chair of the board of directors. 'Future Pak's interest in acquiring Theratechnologies represents a vote of confidence in the company we've built, recognising our achievements in bringing innovative medicines to patients and the outstanding contributions of our dedicated employees.' Last year, Future Pak also made multiple unsuccessful attempts to acquire Vanda Pharmaceuticals, the developer of sleep disorder drug Hetlioz. Cycle Therapeutics ultimately won out, acquiring in a $466m deal. "Theratechnologies shares surge 25% amid $254m Future Pak takeover" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store